203 related articles for article (PubMed ID: 37366913)
1. Systematic Review of Calcineurin Inhibitors and Incidence of Skin Malignancies after Kidney Transplantation in Adult Patients: A Study of 309,551 Cases.
Kulbat A; Richter K; Stefura T; Kołodziej-Rzepa M; Kisielewski M; Wojewoda T; Wysocki WM
Curr Oncol; 2023 Jun; 30(6):5727-5737. PubMed ID: 37366913
[TBL] [Abstract][Full Text] [Related]
2. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
3. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
4. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
[TBL] [Abstract][Full Text] [Related]
5. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
7. A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials.
Deng J; Lu Y; He L; Ou J; Xie H
Turk J Med Sci; 2021 Jun; 51(3):1080-1091. PubMed ID: 33356028
[TBL] [Abstract][Full Text] [Related]
8. The effect of calcineurin inhibitors on anthropometric measurements in kidney transplant recipients.
Sayilar EI; Ersoy A; Ersoy C; Oruc A; Ayar Y; Sigirli D
BMC Nephrol; 2022 Nov; 23(1):375. PubMed ID: 36402951
[TBL] [Abstract][Full Text] [Related]
9. Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients.
Kaufmann RA; Oberholzer PA; Cazzaniga S; Hunger RE
Eur J Dermatol; 2016 Jun; 26(3):265-70. PubMed ID: 26985913
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
[TBL] [Abstract][Full Text] [Related]
11. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
Su L; Tam N; Deng R; Chen P; Li H; Wu L
Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
13. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation.
Asleh R; Clavell AL; Pereira NL; Smith B; Briasoulis A; Alnsasra H; Kremers WK; Habermann TM; Otley CC; Li X; Edwards BS; Stulak JM; Daly RC; Kushwaha SS
J Am Coll Cardiol; 2019 Jun; 73(21):2676-2688. PubMed ID: 31146812
[TBL] [Abstract][Full Text] [Related]
15. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
16. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
17. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
Yan HL; Zong HT; Cui YS; Li N; Zhang Y
Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
